

**NEW YORK STATE MEDICAID
PREFERRED DRUG PROGRAM
2011 THERAPEUTIC CLASS RE-REVIEW**

The New York Medicaid Pharmacy & Therapeutics (P&T) Committee will re-review the following Preferred Drug Program (PDP) therapeutic classes in 2011 (see table below) as new relevant clinical and/or financial information, since the previous review of the class, is known to exist. Meeting agendas for 2011 are under development and will be posted thirty days prior to the meeting date.

2011 PDP Re-Review

Therapeutic Classes	Previous Review Date
Angiotensin Receptor Blockers (ARBs)	March 11, 2010
ARB/Calcium Channel Blocker Combinations	March 11, 2010
ARB/Diuretic Combinations	March 11, 2010
Anti-Emetics	April 29, 2010
Anti-Fungals	September 16, 2010
Antihistamines - Ophthalmic	June 11, 2010
Antihistamines - Oral	June 11, 2010
Anti-Virals - Topical	June 11, 2010
Atypical Antipsychotics	September 16, 2010
Bisphosphonates - Oral	March 11, 2010
Central Nervous System (CNS) Stimulants	April 29, 2010
Dipeptidyl Peptidase (DPP-4) Inhibitors	March 11, 2010
Direct Renin Inhibitors	February 26, 2009
Fluoroquinolones - Ophthalmic	June 11, 2010
HMG-CoA Reductase Inhibitors (Statins)	March 11, 2010
Multiple Sclerosis Agents	June 11, 2010
Narcotics - Long Acting	September 16, 2010
Non-Steroidal Anti-Inflammatory Drugs - Ophthalmic	June 11, 2010
Non-Steroidal Anti-Inflammatory Drugs - Prescription	September 16, 2010
Ophthalmic Prostaglandin Agonists	June 11, 2010
Psoriasis Agents - Topical	June 11, 2010
Sedative Hypnotics/Sleep Agents	April 29, 2010
Serotonin Receptor Agonists (Triptans)	April 29, 2010
Sulfasalazine Derivatives	April 29, 2010
Triglyceride Lowering Agents	March 11, 2010
Urinary Tract Antispasmodics	April 29, 2010

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the Department proposes no changes to the P&T Committee's current recommendations. If interested parties have new relevant clinical information, we encourage that they submit it in a timely manner. The Department will consider the information provided when developing future P&T Committee meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on previous meeting agendas which may be viewed at

http://www.health.ny.gov/health_care/medicaid/program/ptcommittee/

- New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged.
- Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to pandtc@health.state.ny.us (please reference P&T Committee re-review).
- Clinical information submitted in response to a meeting agenda posted on the P&T Committee web-page must be received by the Department no later than two (2) weeks prior to the meeting date or the Committee may not have ample time to review the information.

Please continue to monitor this web-site for meeting schedules and agendas.

Posted: 3/2/2011

Revised: 3/17/2011